HC Wainwright Increases Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Gossamer Bio in a report issued on Monday, November 11th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.18) for the year, up from their prior estimate of ($0.21). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gossamer Bio's Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million.

Separately, Wedbush reaffirmed an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $9.20.

Gossamer Bio Trading Down 3.8 %

GOSS traded down $0.03 during trading hours on Wednesday, reaching $0.82. The company's stock had a trading volume of 1,925,192 shares, compared to its average volume of 1,434,164. The business's 50-day moving average is $0.94 and its 200-day moving average is $0.86. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market cap of $184.81 million, a PE ratio of -2.55 and a beta of 1.96. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. SG Americas Securities LLC purchased a new stake in shares of Gossamer Bio during the 1st quarter worth about $34,000. US Bancorp DE purchased a new stake in Gossamer Bio during the third quarter worth approximately $39,000. Choreo LLC acquired a new stake in shares of Gossamer Bio in the second quarter worth $46,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio in the 3rd quarter valued at $67,000. Finally, Algert Global LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter valued at $75,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.